Renaissance Technologies LLC Sells 157,723 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Renaissance Technologies LLC decreased its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 3.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,853,799 shares of the biopharmaceutical company's stock after selling 157,723 shares during the quarter. Renaissance Technologies LLC owned about 6.61% of Vanda Pharmaceuticals worth $18,460,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its stake in shares of Vanda Pharmaceuticals by 1.4% in the fourth quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company's stock valued at $3,481,000 after purchasing an additional 9,840 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Vanda Pharmaceuticals by 28.0% during the fourth quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company's stock valued at $161,000 after purchasing an additional 7,339 shares in the last quarter. Trexquant Investment LP lifted its position in shares of Vanda Pharmaceuticals by 10.9% during the 4th quarter. Trexquant Investment LP now owns 226,676 shares of the biopharmaceutical company's stock worth $1,086,000 after buying an additional 22,229 shares during the period. Geode Capital Management LLC grew its position in Vanda Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company's stock valued at $6,949,000 after acquiring an additional 24,483 shares during the period. Finally, Wellington Management Group LLP boosted its position in Vanda Pharmaceuticals by 12.7% in the fourth quarter. Wellington Management Group LLP now owns 348,846 shares of the biopharmaceutical company's stock valued at $1,671,000 after buying an additional 39,195 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, April 1st.

Insider Buying and Selling

In other news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $5.02 per share, with a total value of $50,200.00. Following the completion of the purchase, the chief executive officer now directly owns 2,285,731 shares of the company's stock, valued at $11,474,369.62. The trade was a 0.44 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have acquired 32,000 shares of company stock valued at $151,180. 8.90% of the stock is owned by insiders.

Vanda Pharmaceuticals Trading Down 0.9 %

Shares of VNDA stock traded down $0.04 during trading hours on Friday, hitting $4.33. 506,632 shares of the company were exchanged, compared to its average volume of 808,929. The business has a 50 day moving average of $4.59 and a two-hundred day moving average of $4.68. Vanda Pharmaceuticals Inc. has a 52 week low of $3.85 and a 52 week high of $6.75. The company has a market capitalization of $252.51 million, a PE ratio of -13.53 and a beta of 0.72.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million during the quarter, compared to analysts' expectations of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. On average, research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.